ClinicalTrials.gg
RecruitingNCT06524856Updated Oct 19, 2026

The Increase of Lung Capacity Using the Lung Master (Pulmonary Exerciser)

An interventional study of Lung Master (Pulmonary Exerciser) in Dyspnea, Chronic Obstructive Pulmonary Disease and Asthma, sponsored by University of Nebraska. Recruiting at 1 site in United States. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by University of Nebraska · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Oct 19, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 214 studies in Dyspnea with a site in United States — 31 open to participants now, 37 under way, 1 of them phase 3. Dyspnea · United States.

Planned enrollment
103rd of 151
20 · median 36
Started
2024
with 12 others
No phase
84 of 214
18 open now
Primary completion
2027-03
later than 14 of 36 live
Registered
189th of 214
by date

Among the 214 studies in Dyspnea with a site in United States, this one is the 103rd largest by planned enrollment of the 151 interventional ones that give a count, is one of 13 that started in 2024, is one of 84 with no phase, reaches primary completion later than 14 of the 36 other live ones, and was the 189th registered.

Dyspnea

895 studies on the registry are indexed under Dyspnea; 189 are open to participants now.

Browse Dyspnea studies →

Open to participants now

31 of the 214 studies in Dyspnea with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 125 Dyspnea studies recruiting now, 68 (54%) set no upper age limit and 41 (33%) stop at 75 or younger; 18 take children under 18; 23 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies in Dyspnea with a site in United States, or all of them as a file.
02

Study summary

Investigators are studying how a device called The Lung Master device can help people breathe better. The investigational device increases the amount of air our lungs can hold, which is important for overall lung health. The Lung Master is not approved by the FDA.

The study has two visits approximately one month apart. In the first visit participants will take a spirometry test, particularly forced vital capacity (FVC), to measure volume change in the lungs. Participants will take the investigational device home to use daily, either in the morning or evening. Use will be recorded in a diary. After one month, participants will return for another spirometry test. Each study visit will take about one to two hours to complete.

Read the detailed description

Shortness of breath,or dyspnea, occurs when the lungs do not receive enough oxygen leading to discomfort when breathing. This occurs in a quarter of individuals seen in an outpatient setting. Several factors can relate to breathlessness, including lung disorders, heart conditions, or stress. Patients with breathlessness often experience physical limitations in their daily activities. Various treatments for dyspnea are available, however, chronic breathlessness syndrome, such as asthma or chronic obstructive pulmonary disease (COPD), still can persist even when treatment is available.

The Lung Master (Pulmonary Exerciser) is a breathing device used for the respiratory treatment and rehabilitation of chronic breathlessness syndrome. The Lung Master increases resistance during inhalation and exhalation, which works to strengthen the respiratory muscle and improve overall lung function. Therefore, this study will focus on determining how the Lung Master increases lung capacity in healthy individuals. The device is considered investigational and has not been approved by the FDA.

Two groups of healthy participants will be sought for the study: ages 19 to 35 and ages 65 and above. Each participant will have two in-office study visits approximately one month apart. Each visit will take around one to two hours to complete. At the visits, a breathing test called a spirometry test will be done. During the one month interim, the study device will be used at home and the use recorded in a diary. The device must be used least once every day, either in the morning or in the evening for 5 to 20 minutes. You will be contacted after two weeks, and then return the device at the second study visit.

03

Conditions studied

  • Dyspnea
  • Chronic Obstructive Pulmonary Disease
  • Asthma
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • able to complete the at home portion of the study daily
  • fall within the age ranges: 19-35 and above 65 years old

Exclusion criteria

Exclusion Criteria:

  • any respiratory or chronic conditions
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Lung Function in Young and Older Adults

    Lung functions will be assess for two groups: young and older adults. The age range of 19 to 35 is categorized as young adulthood. This age range was selected because the lungs mature around 19-25 years old. The age range above 65 is designated as late adulthood, where lung function gradually declines.

    Device: Lung Master (Pulmonary Exerciser)

Interventions

  • DeviceLung Master (Pulmonary Exerciser)

    During the one-month using the Lung Master at their house, the participant will be using it at least one time every day, either in the morning or in the evening before going to sleep. During the session, the participants will sit upright and try to prolong the inhalation and exhalation breaths through the Lung Master device for at least three seconds. For each session, the participants will try to concentrate on 35-50 breaths in and breaths out which is about 2-5 minutes. Every session can involve using the Pulmonary Exerciser for a minimum of 5 minutes and a maximum of 20 minutes. After each session, participants will be asked to note how long they have used the device and when they have used it. Information from each session will be recorded on the Participant Device Log that will be provided.

06

What researchers measure

Primary outcomes

  1. Inspiratory Capacity

    After reaching the end of a normal, quiet expiration, the maximum volume of air that can be inspired will be measured.

    Time frame: baseline and after one month of device use

  2. Tidal Volume

    The amount of air that moves in or out of the lungs with each respiratory cycle will be measured.

    Time frame: baseline and after one month of device use

07

Study locations

1 of 1 sites recruiting
  • Biomechanics Research Building
    Omaha, Nebraska 68182, United States
    Recruiting
08

References and documents

Publications

  • Berliner D, Schneider N, Welte T, Bauersachs J. The Differential Diagnosis of Dyspnea. Dtsch Arztebl Int. 2016 Dec 9;113(49):834-845. doi: 10.3238/arztebl.2016.0834. PubMed 28098068 ↗
  • Sandberg J, Olsson M, Ekstrom M. Underlying conditions contributing to breathlessness in the population. Curr Opin Support Palliat Care. 2021 Dec 1;15(4):219-225. doi: 10.1097/SPC.0000000000000568. PubMed 34610625 ↗
  • David S, Goldin J, Edwards CW. Forced Expiratory Volume. 2024 Oct 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK540970/ PubMed 31082014 ↗
  • Nguyen JD, Duong H. Pursed-lip Breathing. 2025 Jan 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK545289/ PubMed 31424873 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Mar 2027, 29 months after the start.

Of 268 non-industry interventional studies with no phase under Dyspnea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 29 months is above that.

Counting every sponsor, half of 284 studies reached it within 13 months; a quarter within 6 and three quarters within 29.

Completion moved once since we started tracking on Sep 25, 2026: Mar 2027 → Mar 2029, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2024
First posted
Jul 29, 2024
StartActual
Oct 1, 2024
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2029was Mar 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Mar 2027→Mar 1, 2029
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Study completion Mar 2027→Mar 1, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06524856
Responsible party
Sponsor
First posted
Jul 29, 2024
Start date
Oct 1, 2024
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2029 (estimated)
Last update
Oct 19, 2026

Study contacts

Ann Nguyen, BS
Contact
annnguyen@unomaha.edu
402-554-2383
Jania Williams, MS
Contact
janiawilliams@unomaha.edu
404-895-7610
Farahnaz Fallah Tafti, PhD
principal investigator · University of Nebraska

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion